PHILADELPHIA & BOSTON–(BUSINESS WIRE)–Thomas Jefferson University and Sempresto, Inc. are pleased to announce an exclusive licensing agreement for a novel epinephrine autoinjector designed to improve accessibility and ease of use for patients with severe allergies. This breakthrough device, originally developed at Jefferson, will be further advanced and commercialized by Sempresto under the agreement. Sempresto, Inc., co-founded by Shawn Marcell, Executive Chairman and a veteran entrepreneur